The New York Times, June 7, 2022 (with Rebecca Robbins)
A federal advisory committee on Tuesday voted to recommend that regulators authorize a Covid-19 vaccine made by Novavax, an early beneficiary of the government’s Operation Warp Speed program.
If the Food and Drug Administration accepts the panel’s recommendation on the Novavax two-dose vaccine, it would become the fourth shot to win clearance for adults in the United States. But before the agency could authorize the shots, the F.D.A. would need to sign off on Novavax’s manufacturing process, which has stumbled again and again over the course of two years.
Those ongoing issues are likely to mean the vaccine would not be available for weeks, in contrast to the already cleared Covid vaccines that became available just days after the same committee endorsed those shots. The Centers for Disease Control and Prevention must also recommend use of the shots before they could become available. Continue reading “F.D.A. advisers recommend the authorization of Covid shots by Novavax, a latecomer in the vaccine race.”